Abstract:Abstract Neoadjuvant chemotherapy (NAC) is the standard of care for locally advanced breast cancer (LABC). However, the lack of efficient method to predict the treatment response and prognosis limits the clinical evaluation of the patient eligibility. Elevated lymphocyte-to-monocyte ratio (LMR) has been reported to be associated with favorable prognosis in some hematology malignancies and nasopharyngeal carcinoma, but has not been studied in breast cancer. The purpose of this study is to evaluate whether the LMR is a predictor of the curative impact of LABC patients after NAC and short/long-term mortality. A retrospective cohort of 542 LABC patients who received NAC was recruited between May 2002 and August 2011. The counts for peripheral absolute lymphocyte and monocyte before NAC were retrieved, and the LMR was calculated. Receiver operating characteristic curve analysis, univariate and multivariate Cox proportional hazards analyses were applied to evaluate the associations of LMR with overall survival (OS) and disease-free survival (DFS) respectively. Univariate analysis revealed that higher LMR level (≥4.25) was significantly related to better overall response rate (P = 0.005). Univariate analysis revealed that higher LMR level (≥4.25) was significantly associated with superior OS (P = 0.014), DFS (P = 0.009). The higher lymphocyte count (≥1.5×109/L) was significantly associated with better OS (P = 0.035), while the lower monocyte count (<0.4×109/L) was associated with better OS (P = 0.007) and DFS (P = 0.01), respectively. Multivariate Cox proportional hazard analysis showed that higher LMR level was a significantly independent predictor for superior OS (hazard ratio or HR = 0.636, 95% confidence interval or 95% CI = 0.432-0.937; P = 0.022), DFS (HR = 0.666, 95% CI = 0.495-0.896; P = 0.007) respectively. The traditional predictive factors, including tumor size, lymph node status, hormone receptor status and HER2 status, were also independent prognostic factors of OS and DFS. The elevated pre-NAC peripheral LMR level was a significant favorable factor for NAC LABC prognosis and this easily accessed variable may serve as a potent marker to predict the outcomes of LABC patients after NAC. Citation Format: Lei Wang, Xiao-Jian Ni, Guo-Wei Qian, Qian-Wen Ou-Yang, Xiao-Lan Zhang, Yi-Zhou Jiang, Sheng Chen, Xin Hu, Zhi-Ming Shao. Elevated peripheral blood lymphocyte-to-monocyte ratio predicts favorable response and prognosis in locally advanced breast cancer after neoadjuvant chemotherapy [abstract]. In: Proceedings of the Thirty-Seventh Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2014 Dec 9-13; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2015;75(9 Suppl):Abstract nr P3-11-09.

The Peripheral Blood Neutrophil-To-Lymphocyte Ratio Is Superior To The Lymphocyte-To-Monocyte Ratio For Predicting The Long-Term Survival Of Triple-Negative Breast Cancer Patients

Neutrophil-lymphocyte Ratio As a Prognostic Factor for Stereotactic Body Radiotherapy Treatment of Metastatic Liver Tumors.

The Prognostic Value of Platelet-Lymphocyte Ratio and Neutrophil-Lymphocyte Ratio in the Treatment Response and Survival of Patients with Peripheral T-cell Lymphoma.

Lymphocyte-to-Monocyte Ratio is Associated with the Poor Prognosis of Breast Cancer Patients Receiving Neoadjuvant Chemotherapy

Prognostic role of pretreatment neutrophil to lymphocyte ratio in breast cancer patients: A meta-analysis.

Prognostic Role of Pretreatment Neutrophil to Lymphocyte Ratio in Breast Cancer Patients

An Elevated Peripheral Blood Lymphocyte-to-Monocyte Ratio Predicts Favorable Response and Prognosis in Locally Advanced Breast Cancer Following Neoadjuvant Chemotherapy

Elevated preoperative neutrophil-to-lymphocyte ratio predicts poor disease-free survival in Chinese women with breast cancer

Abstract P3-11-09: Elevated Peripheral Blood Lymphocyte-to-monocyte Ratio Predicts Favorable Response and Prognosis in Locally Advanced Breast Cancer after Neoadjuvant Chemotherapy

Prognostic Value of Pretreatment Neutrophil-to-Lymphocyte Ratio in HER2-Positive Metastatic Breast Cancer

Novel Lymphocyte to Red Blood Cell Ratio (LRR), Neutrophil to Red Blood Cell Ratio (NRR), Monocyte to Red Blood Cell Ratio (MRR) As Predictive and Prognostic Biomarkers for Locally Advanced Breast Cancer

The Neutrophil Lymphocyte Ratio Is Associated With Breast Cancer Prognosis: An Updated Systematic Review And Meta-Analysis

Abstract P2-05-15: The lymph node ratio as an independent prognostic factor for node-positive triple-negative breast cancer

The Lymph Node Ratio As an Independent Prognostic Factor for Node-Positive Triple-Negative Breast Cancer

Usefulness of Neutrophil-to-lymphocyte Ratio and Platelet-to-lymphocyte Ratio in Hormone-Receptor-negative Breast Cancer.

Usefulness of lymphocyte-to-monocyte, neutrophil-to-monocyte and neutrophil-to-lymphocyte ratios as prognostic markers in breast cancer patients treated with neoadjuvant chemotherapy

Low pretreatment lymphocyte/monocyte ratio is associated with the better efficacy of neoadjuvant chemotherapy in breast cancer patients

The Prognostic Value of Neutrophil-to-lymphocyte Ratio in De Novo Stage IV Breast Cancer: a Retrospective Cohort Study

Neutrophil to Lymphocyte Ratio As a Prognostic Indicator for Advanced Non-Small Cell Lung Cancer Patients: A Retrospective Study.

Prognostic implications of the peripheral platelet-to-lymphocyte ratio and neutrophil-to-lymphocyte ratio in predicting pathologic complete response after neoadjuvant chemotherapy in breast cancer patients

The prognostic value of absolute lymphocyte count and neutrophil‐to‐lymphocyte ratio for patients with metastatic breast cancer: a systematic review and meta‐analysis